{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:08:04Z","timestamp":1762016884389,"version":"build-2065373602"},"reference-count":44,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej19-0283","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:04:09Z","timestamp":1574114649000},"page":"219-229","source":"Crossref","is-referenced-by-count":9,"title":["Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients"],"prefix":"10.1507","volume":"67","author":[{"given":"Saya","family":"Nagasawa","sequence":"first","affiliation":[{"name":"Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, 350-1241 Saitama, Japan"},{"name":"Department of Obstetrics and Gynecology, Juntendo University, Bunkyo-ku, 113-8431 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, 350-1241 Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniko","family":"Horie-Inoue","sequence":"additional","affiliation":[{"name":"Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, 350-1241 Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka 350-1298 Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Juntendo University, Bunkyo-ku, 113-8431 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka 350-1298 Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, 350-1241 Saitama, Japan"},{"name":"Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku 173-0015 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","unstructured":"1 Center for Cancer Control and Information Services, National Cancer Canter, Japan. Projected Cancer Statistics, 2018. (https:\/\/ganjoho.jp\/en\/public\/statistics\/short_pred.html)"},{"key":"2","doi-asserted-by":"crossref","unstructured":"3 Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14: 9\u201332.","DOI":"10.20892\/j.issn.2095-3941.2016.0084"},{"key":"3","doi-asserted-by":"crossref","unstructured":"4 Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, et al. (2017) Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 28: e32.","DOI":"10.3802\/jgo.2017.28.e32"},{"key":"4","doi-asserted-by":"publisher","unstructured":"5 Weinstein IB (2002) Cancer. Addiction to oncogenes\u2013the Achilles heal of cancer. Science 297: 63\u201364.","DOI":"10.1126\/science.1073096"},{"key":"5","doi-asserted-by":"publisher","unstructured":"6 Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7 Hayano T, Yokota Y, Hosomichi K, Nakaoka H, Yoshihara K, et al. (2014) Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer. PLoS One 9: e114491.","DOI":"10.1371\/journal.pone.0114491"},{"key":"7","doi-asserted-by":"crossref","first-page":"112258","DOI":"10.18632\/oncotarget.22733","volume":"8","author":"A Hirasawa","year":"2017","unstructured":"8 Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, et al. (2017) Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget 8: 112258\u2013112267.","journal-title":"Oncotarget","ISSN":"https:\/\/id.crossref.org\/issn\/1949-2553","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9 Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, et al. (2019) The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer 29: 1043\u20131049.","DOI":"10.1136\/ijgc-2019-000384"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10 Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, et al. (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13: 385\u2013394.","DOI":"10.1016\/S1470-2045(11)70404-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11 Mabuchi S, Sugiyama T, Kimura T (2016) Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol 27: e31.","DOI":"10.3802\/jgo.2016.27.e31"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12 Shibuya Y, Tokunaga H, Saito S, Shimokawa K, Katsuoka F, et al. (2018) Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Genes Chromosomes Cancer 57: 51\u201360.","DOI":"10.1002\/gcc.22507"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13 Ishikawa M, Nakayama K, Nakamura K, Ono R, Sanuki K, et al. (2018) Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients. Oncotarget 9: 14754\u201314763.","DOI":"10.18632\/oncotarget.24546"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14 Cho KR, Shih IeM (2009) Ovarian cancer. Annu Rev Pathol 4: 287\u2013313.","DOI":"10.1146\/annurev.pathol.4.110807.092246"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15 Gadducci A, Lanfredini N, Tana R (2014) Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecol Endocrinol 30: 612\u2013617.","DOI":"10.3109\/09513590.2014.926325"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16 Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, et al. (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90: 378\u2013381.","DOI":"10.1016\/S0090-8258(03)00264-6"},{"key":"16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12885-015-1421-8","volume":"15","author":"R Mackenzie","year":"2015","unstructured":"17 Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, et al. (2015) Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 15: 415.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18 Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, et al. (2015) Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. Int J Oncol 46: 2389\u20132398.","DOI":"10.3892\/ijo.2015.2951"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19 Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, et al. (2018) Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. Br J Cancer 119: 1060\u20131066.","DOI":"10.1038\/s41416-018-0268-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20 Li C, Bonazzoli E, Bellone S, Choi J, Dong W, et al. (2019) Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proc Natl Acad Sci U S A 116: 619\u2013624.","DOI":"10.1073\/pnas.1814027116"},{"key":"20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"21 Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, et al. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451: 1116\u20131120.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22 Kircher M, Witten DM, Jain P, O\u2019Roak BJ, Cooper GM, et al. (2014) A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46: 310\u2013315.","DOI":"10.1038\/ng.2892"},{"key":"22","doi-asserted-by":"publisher","unstructured":"23 Gurung A, Hung T, Morin J, Gilks CB (2013) Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology 62: 59\u201370.","DOI":"10.1111\/his.12033"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24 Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, et al. (2002) Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 21: 407\u2013411.","DOI":"10.1097\/00004347-200210000-00011"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30: 2654\u20132663.","DOI":"10.1200\/JCO.2011.39.8545"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26 Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, et al. (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307: 382\u2013390.","DOI":"10.1001\/jama.2012.20"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27 Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, et al. (2008) Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26: 20\u201325.","DOI":"10.1200\/JCO.2007.11.6905"},{"key":"27","unstructured":"28 Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, et al. (2008) \u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26: 5530\u20135536."},{"key":"28","doi-asserted-by":"crossref","unstructured":"29 Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, et al. (2011) Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 22: 1346\u20131352.","DOI":"10.1093\/annonc\/mdq628"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30 Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557\u20131565.","DOI":"10.1001\/jama.2011.1456"},{"key":"30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"31 Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245\u2013251.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32 Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, et al. (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triplenegative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852\u2013861.","DOI":"10.1016\/S1470-2045(11)70214-5"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33 Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, et al. (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43: 879\u2013882.","DOI":"10.1038\/ng.893"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34 McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 66: 8109\u20138115.","DOI":"10.1158\/0008-5472.CAN-06-0140"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35 Sugano K, Nakamura S, Ando J, Takayama S, Kamata H, et al. (2008) Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast\/ovarian cancer. Cancer Sci 99: 1967\u20131976.","DOI":"10.1111\/j.1349-7006.2008.00944.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36 Choi MC, Jang JH, Jung SG, Park H, Joo WD, et al. (2018) Unclassified variants of BRCA1 and BRCA2 in Korean patients with ovarian cancer. Int J Gynecol Cancer 28: 308\u2013315.","DOI":"10.1097\/IGC.0000000000001161"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37 Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis associated ovarian carcinomas. N Engl J Med 363: 1532\u20131543.","DOI":"10.1056\/NEJMoa1008433"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38 Worley MJ Jr, Liu S, Hua Y, Kwok JS, Samuel A, et al. (2015) Molecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer 51: 1831\u20131842.","DOI":"10.1016\/j.ejca.2015.05.011"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39 Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, et al. (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597\u20131601.","DOI":"10.2353\/ajpath.2009.081000"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40 Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, et al. (2012) Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 43: 2197\u20132206.","DOI":"10.1016\/j.humpath.2012.03.011"},{"key":"40","unstructured":"41 Terada T (2012) Endometrioid adenocarcinoma of the ovary arising in atypical endometriosis. Int J Clin Exp Pathol 5: 924\u2013927."},{"key":"41","doi-asserted-by":"crossref","unstructured":"42 Kurman RJ, Shih IeM (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014Shifting the paradigm. Hum Pathol 42: 918\u2013931.","DOI":"10.1016\/j.humpath.2011.03.003"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43 Guan L, Zhu S, Han Y, Yang C, Liu Y, et al. (2018) Knockout of CTNNB1 by CRISPR-Cas9 technology inhibits cell proliferation through the Wnt\/\u03b2-catenin signaling pathway. Biotechnol Lett 40: 501\u2013508.","DOI":"10.1007\/s10529-017-2491-2"},{"key":"43","unstructured":"44 Sun Z, Bhagwate A, Prodduturi N, Yang P, Kocher JA (2017) Indel detection from RNA-seq data: tool evaluation and strategies for accurate detection of actionable mutations. Brief Bioinform 18: 973\u2013983."},{"key":"44","doi-asserted-by":"crossref","unstructured":"45 O\u2019Brien TD, Jia P, Xia J, Saxena U, Jin H, et al. (2015) Inconsistency and features of single nucleotide variants detected in whole exome sequencing <i>versus<\/i> transcriptome sequencing: a case study in lung cancer. Methods 83: 118\u2013127.","DOI":"10.1016\/j.ymeth.2015.04.016"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/2\/67_EJ19-0283\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T03:47:16Z","timestamp":1582948036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/2\/67_EJ19-0283\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0283","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"type":"print","value":"0918-8959"},{"type":"electronic","value":"1348-4540"}],"subject":[],"published":{"date-parts":[[2020]]}}}